Change 5-day change 1-year change 3-year change Capi.($)
+5.60%-6.13% - - 30Cr
+0.99%+1.78%+4.07%+16.73% 4.95TCr
+3.71%+9.40%+486.98%+592.14% 4.36TCr
+2.70%+1.57%+33.39%+8.85% 3.93TCr
+5.60%+10.21%+16.76%+85.72% 3.96TCr
+2.21%+6.75%+21.31%+53.37% 3.24TCr
+2.23%+4.71% - - 1.68TCr
+0.97%+2.35%+37.75%+126.84% 1.65TCr
-0.11%+2.41%+6.24%+18.87% 1.4TCr
+0.75%+15.04%+78.59%+30.30% 1.28TCr
Average +2.47%+6.32%+85.64%+116.60% 2.94TCr
Weighted average by Cap. +2.54%+6.10%+104.25%+140.79%
Logo OvaScience Inc
Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company's two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.
Employees
-